• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Solana Company

    5/1/26 4:34:05 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    DEFA14A 1 tm2612975-1_defa14a.htm DEFA14A tm2612975-1_defa14a - none - 1.7656368s
    ​
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.    )
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ​
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ​
    ☐
    Definitive Proxy Statement
    ​
    ☒
    Definitive Additional Materials
    ​
    ☐
    Soliciting Material Pursuant to § 240.14a-12
    ​
    SOLANA COMPANY
    ​
    (Name of Registrant as Specified In Its Charter)​
     
    ​
    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)​
    Payment of Filing Fee (Check all boxes that apply)
    ☒
    No fee required.
    ​
    ☐
    Fee paid previously with preliminary materials.
    ​
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ​

    ​
     
    SOLANA COMPANY
    642 Newtown Yardley Road, Suite 100
    Newtown, Pennsylvania 18940
    AMENDED NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
    TO BE HELD ON MAY 21, 2026
    Notice is hereby given that the 2026 Annual Meeting of Stockholders of Solana Company (the “Company,” “we” or “us”) will be held on Thursday, May 21, 2026, at 9:00 a.m. Eastern Time, as a virtual meeting at www.virtualshareholdermeeting.com/HSDT2026. This amended notice replaces the notice previously filed by us with the Securities and Exchange Commission on April 10, 2026 and mailed to our stockholders of record in connection with the solicitation of proxies by our board of directors at the Annual Meeting (as defined below).
    At the 2026 Annual Meeting of Stockholders or any adjournment or postponement thereof (the “Annual Meeting”), you will be asked to consider and vote upon the following proposals:
    •
    Proposal 1 — To elect five directors named in the proxy statement of the Company, filed with the Securities Exchange Commission on April 10, 2026 (the “proxy statement”), each to serve for a one-year term until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal;
    ​
    •
    Proposal 2 — To ratify the appointment of CBIZ CPAs P.C., as our independent registered public accounting firm for the year ending December 31, 2026; and
    ​
    •
    Proposal 3 — To elect two additional directors named in the accompanying proxy supplement, each to serve for a one-year term until the 2027 annual meeting of stockholders and until his successor is duly elected and qualified and until his earlier death, resignation or removal.
    ​
    We expect to conduct any other business properly brought before the Annual Meeting.
    Through the website above, you will be able to attend the Annual Meeting online, vote electronically, view the list of stockholders entitled to vote at the Annual Meeting and submit your questions during the Annual Meeting. Your attention is directed to the proxy statement and accompanying proxy supplement, where details regarding how to attend the Annual Meeting online and the foregoing items of business are more fully described. The Board of Directors previously fixed the close of business on April 1, 2026 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting. Only stockholders of record at the close of business on April 1, 2026 are entitled to receive notice of, and to vote at, the Annual Meeting and any adjournment thereof.
    Our Board of Directors unanimously recommends that you vote FOR the election of each director nominee, FOR Proposal 2 and FOR the election of each additional director nominee.
    Your vote is extremely important, regardless of the number of shares of Class A common stock you own.   Whether or not you plan to virtually attend the Annual Meeting, you are respectfully requested by the Board of Directors to promptly submit your proxy by telephone or over the Internet in accordance with the instructions on the proxy card or voting instruction card or, if you received a printed proxy card by mail, sign, date and return the proxy card or voting instruction card. If you received this notice and the proxy statement and/or accompanying proxy supplement in the mail, a return envelope is enclosed for your convenience. This will not prevent you from voting at the Annual Meeting since you may revoke your proxy at any time prior to the Annual Meeting or vote electronically at the Annual Meeting, but submitting your proxy will help to ensure the presence of a quorum at the Annual Meeting and avoid added proxy solicitation costs.
     

    ​
     
    By Order of the Board of Directors,
    [MISSING IMAGE: sg_jeffmathieson-bw.jpg]
    Jeffrey S. Mathiesen
    Chief Financial Officer, Treasurer and Secretary
    Newtown, Pennsylvania
    May 1, 2026
     

    ​
     
    SOLANA COMPANY
    SUPPLEMENT TO PROXY STATEMENT
    FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS
    This supplement (“Supplement”) relates to the notice of annual meeting of stockholders and proxy statement (the “Proxy Statement”) of Solana Company, a Delaware corporation (sometimes referred to as “the Company,” “we” and “our”), previously filed by us with the Securities and Exchange Commission on April 10, 2026 and furnished to our stockholders in connection with the solicitation of proxies by our board of directors (the “Board”) for the 2026 annual meeting of stockholders to be held on May 21, 2026, or any postponement or adjournment thereof (the “Annual Meeting”).
    Subsequent to the filing of the Proxy Statement, as disclosed on the Company Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on April 24, 2026, Sherrie Perkins and Paul Buckman notified the Company of their decision to not stand for re-election as directors when their current terms expire at the Annual Meeting. Additionally, the Board increased the size of the Board from seven to nine members, creating two vacancies on the Board, and appointed Michel Lee and Sergio Mello as directors to fill the newly created vacancies.
    This Supplement, dated May 1, 2026, is being made available to our stockholders on or about May 1, 2026, in connection with the solicitation of proxies by the Board for the Annual Meeting. This Supplement, which adds to and amends the Proxy Statement, includes updated information relating to the above-mentioned director transitions and a new proposal to elect two additional directors to the Board, and includes an amended notice and proxy card.
    New Proposal 3 — Election of Additional Directors.   Proposal 3, which has been added to the agenda for the Annual Meeting, proposes that Messrs. Lee and Mello be re-elected at the Annual Meeting, each to serve for a one-year term until the 2027 annual meeting of stockholders and until his successor is dully elected and qualified and until his earlier death, resignation or removal.
    The amended proxy card or voting instruction form enclosed with this Supplement differs from the proxy card or voting instruction form previously furnished to you with the Proxy Statement dated April 10, 2026. The enclosed proxy card or voting instruction form includes the election of the additional director nominees as a new Proposal 3. If you have already voted, we encourage you to resubmit your vote on all three proposals by submitting the amended proxy card or voting instruction form enclosed with this Supplement or by submitting a proxy by telephone or through the Internet by following the procedures on your amended proxy card or voting instruction form. However, if you return, or have returned, an original proxy card or voting instruction form, your proxy will still remain valid for all of the other proposals and director nominees except Messrs. Lee and Mello because they are not listed as nominees on the original proxy card or voting instruction form, and will be voted at the Annual Meeting unless revoked. PLEASE NOTE THAT IF YOU SUBMIT A NEW PROXY CARD OR VOTING INSTRUCTION FORM, IT WILL REVOKE ALL PRIOR PROXY CARDS OR VOTING INSTRUCTION FORMS, SO IT IS IMPORTANT TO INDICATE YOUR VOTE ON EACH PROPOSAL ON THE NEW PROXY CARD OR VOTING INSTRUCTION FORM.
    Except for the as supplemented by the information contained herein, including new Proposal 3, and the amended notice and proxy card, this Supplement does not modify, amend, supplement or otherwise affect any matter presented for consideration in the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement, which contains important additional information. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby.
    Important Notice Regarding the Availability of Proxy Materials for the Solana Company Annual Meeting of Stockholders to be Held on Thursday, May 21, 2026: The Amended Notice of Annual Meeting of Stockholders, proxy statement and accompanying proxy statement and annual report to stockholders are available at www.proxyvote.com.
     
    1

    ​
     
    Withdrawal of Director Nominees
    Prior to providing their resignation, Sherrie Perkins and Paul Buckman were each a director nominee standing for re-election to the Board as the Annual Meeting, as described in Proposal 1 — Election of Directors. As a result of their resignations, Ms. Perkins and Mr. Buckman will no longer stand for re-election to the Board. The five other director nominees named in Proposal 1 in the Proxy Statement — Joseph Chee, Dane C. Andreeff, Blane Walter, Edward M. Straw and Cosmo Jiang — will continue to stand for re-election at the Annual Meeting. In addition, the two additional directors — Michel Lee and Sergio Mello — named in Proposal 3 in this Supplement, will stand for re-election at the Annual Meeting. In connection with Ms. Perkins’ and Mr. Buckman’s resignations, the Board approved a decrease in the authorized number of directors on the Board from nine to seven, effective as of immediately prior to the Annual Meeting.
     
    2

    ​
     
    PROPOSAL 3 — ELECTION OF ADDITIONAL DIRECTORS
    On April 23, 2026, the Board increased the size of the Board from seven to nine members, creating two vacancies on the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed each of Michel Lee and Sergio Mello as directors to fill the newly created vacancies, effective immediately. The Board proposed that Messrs. Lee and Mello be re-elected at the Annual Meeting to serve for a one-year term until the 2027 annual meeting of stockholders and until his successor is duly elected and qualified and until his earlier death, resignation or removal.
    The following are brief biographies of Messrs. Lee and Mello that include information, as of the date of this Supplement, regarding the specific and particular experience, qualifications, attributes or skills of Messrs. Lee and Mello that led the Board to believe that Messrs. Lee and Mello should serve on the Board. However, each of the members of the Board may have a variety of reasons why he or she believes Messrs. Lee and Mello would be an appropriate nominee for the Board, and these views may differ from the views of other members.
    Name
    ​ ​
    Position(s)
    ​ ​
    Age
    ​
    Michel Lee ​ ​ Director ​ ​
    56
    ​
    Sergio Mello ​ ​ Director ​ ​
    44
    ​
    Michel Lee
    Michel Lee has been a co-founder and investment partner at Cybertech Partners since October 2018, and co-founder at Hashkey Group Limited (HKEX: 3887.HK) since January 2019. Mr. Lee is a capital market and investment professional with over 25 years of experience in various senior leadership roles in one of the largest global investment banks in Hong Kong, Beijing, Tokyo and London. Mr. Lee has helped various companies to complete strategic transactions including early funding rounds, initial public offerings, structured financings, derivatives, and mergers and acquisitions. Mr. Lee holds a master’s degree in Advanced Information Technology from Imperial College London, and a bachelor’s degree in Physics, Electronics & Computing from University College London. Our Board believes that Mr. Lee is qualified to serve as a director based on his significant experience in the investment industry and capital markets and his knowledge of digital assets.
    Sergio Mello
    Sergio Mello has served as the global head of stablecoin solutions at Anchorage Digital, where he focuses on the business development and platform offerings for stablecoins, since January 2026 and previously served as its head of stablecoins. Prior to joining Anchorage Digital, Mr. Mello served as the founder and chief executive officer of Lago Finance, a consortium of financial institutions designed to enhance settlements with tokenized cash, from April 2022 to November 2023. Mr. Mello is a serial entrepreneur who has achieved exits in web1, web2, and web3. He has also served an advisor to Nodle, a digital trust network, from October 2017 to May 2022 and as a crypto advisor to Reddit, an online open community platform, from January 2021 to December 2021. Mr. Mello holds a bachelor’s degree in Electrical Engineering from Politecnico di Torino. Our Board believes that Mr. Mello is qualified to serve as a director based on his extensive experience in digital assets.
    Independence
    The Board has affirmatively determined that Messrs. Lee and Mello are independent, as defined under the Nasdaq listing standards.
    Stock Ownership
    Messrs. Lee and Mello did not beneficially own any common stock of the Company as of April 1, 2026, the date of the security ownership information disclosed for each of our directors and named executive officers in the section titled “Security Ownership of Certain Beneficial Owners and Management,” beginning on page 29 of the Proxy Statement.
     
    3

    ​
     
    Vote Required
    A plurality of the votes cast FOR a nominee, meaning each director nominee receiving the highest number of votes FOR will be elected. Stockholders may not cumulate votes for directors. Withheld votes will have no effect on this Proposal 3. Brokers do not have discretion to vote on this Proposal 3, absent instructions from their beneficial owners. Broker non-votes will have no effect on this Proposal 3.
    OUR BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF MESSRS. LEE AND MELLO.
     
    4

    ​
     
    VOTING AND REVOCABILITY OF PROXIES
    Please vote as soon as possible using the amended proxy card or voting instruction form enclosed with this Supplement, which includes new Proposal 3 — the election of Messrs. Lee and Mello as directors. If you have already voted, you are not required to vote again. If you would like to vote for the re-election of Messrs. Lee and Mello, however, you must vote again using the amended proxy card or voting instruction form.
    If you return, or have already returned, an original proxy card or voting instruction form, then the votes indicated on such original proxy card or voting instruction form will remain valid for each of the proposals and director nominee elections other than Proposal 3 and will be voted at the Annual Meeting unless revoked. Please note that the submission of a new proxy card will revoke all prior proxy cards or voting instruction forms submitted, so it is important to indicate your vote for each proposal on any new proxy card, including those included on the amended proxy card, the original proxy card or any previously submitted proxy card or voting instruction form.
    If the amended proxy card or original proxy card or voting instruction form is properly signed, dated and returned and is not revoked, the proxy will be voted at the Annual Meeting in accordance with your instructions indicated on the proxy card. If no instructions are given on how to vote your shares, your proxy will be voted in accordance with the Board’s recommendations on the proposals included on such proxy card or voting instruction form.
    You may revoke your proxy and change your vote at any time before your vote is due, including the final vote at the Annual Meeting if you have the right to vote at the Annual Meeting. Attendance at the Annual Meeting will not automatically revoke your proxy unless you vote at the Annual Meeting or specifically request in writing that your prior proxy be revoked.
     
    5

    ​
    [MISSING IMAGE: px_26solanaproxy1pg01-bw.jpg]
    SCAN TOVIEW MATERIALS & VOTE SOLANA COMPANY642 NEWTOWN YARDLEY ROAD, SUITE 100VOTE BY INTERNETNEWTOWN, PA 18940Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of informationup until 11:59 p.m. Eastern Time on May 20, 2026. Have your proxy card in hand whenyou access the web site and follow the instructions to obtain your records and to create anelectronic voting instruction form.During The Meeting - Go to www.virtualshareholdermeeting.com/HSDT2026You may attend the meeting via the Internet and vote during the meeting. Have the informationthat is printed in the box marked by the arrow available and follow the instructions.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions up until11:59 p.m. Eastern Time on May 20, 2026. Have your proxy card in hand when you call andthen follow the instructions. You cannot vote by phone if you plan to vote your preferredshares differently.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope wehave provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,Edgewood, NY 11717.TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:T00338-P50785KEEP THIS PORTION FOR YOUR RECORDSTHIS AMENDED PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.DETACH AND RETURN THIS PORTION ONLYSOLANA COMPANYFor WithholdFor AllTo withhold authority to vote for any individualThe Board of Directors recommends you vote FOR ALL ofAllAllExceptnominee(s), mark "For All Except" and write thenumber(s) of the nominee(s) on the line below.the following director nominees: 1.Election of Directors!!!Nominees:01)Joseph Chee05)Cosmo Jiang02)Blane Walter06)Nominee Withdrawn03)Dane C. Andreeff07)Nominee Withdrawn04)Edward M. StrawThe Board of Directors recommends you vote FOR the following proposals:2.To ratify the appointment of CBIZ CPAs P.C., as our independent registered public accounting firm for the year ending December 31, 2026. 3.Election of Additional Directors Nominees: 3a. Michel Lee 3b. Sergio Mello For Against Abstain! ! !ForWithhold!!!! NOTE: In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the meeting and any adjournment or postponement thereof.Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If an entity, please sign in the full entity name, by a duly authorized officer.[PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date

    ​
    [MISSING IMAGE: px_26solanaproxy1pg02-bw.jpg]
    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:The Proxy Statement and Proxy Supplement are available at www.proxyvote.com.T00339-P50785SOLANA COMPANYAnnual Meeting of StockholdersMay 21, 2026 9:00 a.m. Eastern TimeThis amended proxy is solicited by the Board of DirectorsThe stockholder(s) hereby acknowledges receipt of the Amended Notice of 2026 Annual Meeting of Stockholders dated May 1, 2026 and Proxy Statement, dated April 10, 2026 as supplemented by the Proxy Supplement, dated May 1, 2026, and hereby appoint(s) Joseph Chee, as proxy and attorney-in-fact, with the full power to appoint his substitute, and hereby authorize(s) him to represent and to vote, as designated on the reverse side of this amended proxy card, and to vote in his judgment upon all other matters that may properly come before the Annual Meeting and any adjournment or postponement thereof, all of the shares of Class A common stock of Solana Company that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 9:00 a.m., Eastern Time on May 21, 2026, at www.virtualshareholdermeeting.com/HSDT2026, and any adjournment or postponement thereof. The undersigned hereby revoke(s) any proxy previously given to vote at the Annual Meeting.This amended proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this amended proxy will be voted in accordance with the Board of Directors' recommendations. Continued and to be signed on reverse side

    Get the next $HSDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    4/23/2026$3.00Buy
    B. Riley Securities
    4/6/2026$4.00Buy
    Maxim Group
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    SEC Filings

    View All

    Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Solana Co (0001610853) (Filer)

    5/29/26 5:16:57 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Solana Company

    424B5 - Solana Co (0001610853) (Filer)

    5/29/26 5:08:05 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SD filed by Solana Company

    SD - Solana Co (0001610853) (Filer)

    5/29/26 4:05:58 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    5/26/26 7:30:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Mello Sergio was granted 6,360 shares (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    5/26/26 7:30:11 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lee Michel Kai Tai was granted 6,360 shares (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    5/26/26 7:30:09 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- Jito Foundation, the organization supporting the development of the Jito ecosystem and the team behind the execution infrastructure underpinning the Solana network, today announced a strategic partnership with Solana Company (NASDAQ:HSDT), a leading institutional blockchain infrastructure company for the Solana ecosystem. The partnership is intended to focus on building institutional-grade validator infrastructure, advancing yield optimization, and accelerating institutional adoption of Solana across the APAC region.  Bringing Solana's market layer infrastructure into APAC's financial hubsThrough the collaboration, Solana Company and the Jito Founda

    5/6/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Solana Company with a new price target

    B. Riley Securities initiated coverage of Solana Company with a rating of Buy and set a new price target of $3.00

    4/23/26 8:09:25 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on Solana Company with a new price target

    Maxim Group resumed coverage of Solana Company with a rating of Buy and set a new price target of $4.00

    4/6/26 8:28:30 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth

    Gani is a proven transformation leader with track record at Hedera Hashgraph, Aptos, Gemini Space Station, and JUUL Labs. She joins to accelerate Solana Company's next phase of growth.Gani brings deep financial and operational expertise in public companies, global financial infrastructure buildout, and operational scaling that has driven hundreds of millions in value creation across hyper-growth companies.Strategic hire signals Solana Company's commitment to institutional-grade operations as it expands its digital asset treasury and infrastructure globally. NEWTOWN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) today announced the appointment of Madelene Gani, CPA,

    4/9/26 4:15:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care